Search filters
Filters
Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 148
  • 17
  • 396
  • 1237
  • 588
  • 29
  • 49
  • 3
  • 1162
  • 1237
  • 6
  • 3
  • 1240

Found 1243 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

NIH RECOVER: Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults

18 years - 60 years
Accepts healthy volunteer
All genders
This study seeks to understand why some people who got COVID-19 are still sick many months after being infected, and how this affects the body. Being sick for a long time is sometimes called “Long COVID” or “PASC”, which stands for post-acute sequelae of SARS-CoV-2 infection. Through this study, we …
Learn More
Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel

Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel

18 years - 99 years
All genders
Interventional
Participants invited to participate in a research study must have diagnosis of multiple myeloma and have been previously treated with the study drug, cilta-cel. The purpose of this research is to monitor the health status of subjects who were previously enrolled in cilta-cel.
Learn More

Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)

18 years - 99 years
All genders
The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations.
Learn More

Study of drug PB2452 in Ticagrelor-Treated Patients with Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure

18 years - 99 years
All genders
Phase 3
Interventional
The research study is being conducted to test the study drug PB2452 to see if it is safe and will reverse the bleeding effects of Brilinta® (also known as ticagrelor). Candidates must be taking Brilinta® (ticagrelor) or show intake within the past 3 days. They will be considered for participation …
Learn More

UPCC 04122 A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors

99 years or below
All genders
Phase 1
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More
UPCC 11522 A Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma

UPCC 11522 A Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma

99 years or below
All genders
This phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells.
Learn More

EA5163/S1709 INSIGNA: A Randomized Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous NonSmall Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNaturedriven Analysis

99 years or below
All genders
This study is being done to answer the following questions: Does starting treatment with the immunotherapy drug, MK-3475 (pembrolizumab), alone, instead of a combination of immunotherapy and chemotherapy, result in a significant improvement in overall survival (OS) (time being alive) for patients with your type of cancer? Does additional treatment …
Learn More

App for Strengthening Services In Specialized Therapeutic Support

18 years - 99 years
All genders
Observational
Through this project, the research team will test an app developed for tracking data collection with 30 support staff from three agencies. After observing and interviewing support staff and their supervisors, we created two different mobile apps for support staff to use that we think can be helpful when they …
Learn More

UPCC 01622 Neoadjuvant PD-1 blockade in resectable Merkel cell carcinoma

99 years or below
All genders
Phase 1
Please refer to Protocol Section 3.0 (Objective(s), Hypothesis(es), and Endpoint(s). Please refer to Protocol Section 3.0 (Objective(s), Hypothesis(es), and Endpoint(s). Please reer to Protocol Section 3.2 (Secondary Objective(s), Hypothesis(es), and Endpoint(s)
Learn More

UPCC 09922 A Phase 1 Open-label Multicenter Dose-ranging Study to Investigate Safety and Tolerability Efficacy Pharmacokinetics Pharmacodynamics and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1

99 years or below
All genders
Phase 1
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More
1131 - 1140 of 1243